Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Novel TG-FGFR1 and TRIM33-NTRK1 transcript fusions in papillary thyroid carcinoma.
|
30664823 |
2019 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Among enrolled patients harbouring TRK fusion-positive cancers, eight (47%) had infantile fibrosarcoma, seven (41%) had other soft tissue sarcomas, and two (12%) had papillary thyroid cancer.
|
29606586 |
2018 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
We exploited the MassARRAY (MA) genotyping platform to develop the "PTC-MA assay", which allows the simultaneous detection of 13 hotspot mutations, in the BRAF, KRAS, NRAS, HRAS, TERT, AKT1, PIK3CA, and EIF1AX genes, and six recurrent genetic rearrangements, involving the RET and TRK genes in papillary thyroid cancer (PTC).
|
29214440 |
2018 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Seven of 27 PTCs (26%) had neurotrophic tyrosine kinase receptor (NTRK) fusion oncogenes (NTRK type 3/ets variant 6 [NTRK3/ETV6], n =5; NTRK3/unknown, n = 1; and NTRK type 1/translocated promoter region, nuclear basket protein [NTRK1/TPR], n = 1), including 5 tumors that measured >2 cm and 3 that diffusely involved the entire thyroid or lobe.
|
26784937 |
2016 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The purpose of this study is to describe a case of concurrent medullary and papillary thyroid carcinoma (MTC and PTC) and cutaneous melanoma and to analyze BRAF(V600E) mutation in plasma and tissues.
|
24858900 |
2014 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTC, the most frequent thyroid carcinoma histotype, is associated with gene rearrangements that generate RET/PTC and TRK oncogenes and with BRAF-V600E and RAS gene mutations.
|
23132790 |
2013 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
PTC is associated with gene rearrangements generating RET/PTC and TRK oncogenes, and to the BRAFV600E activating point mutation.
|
21339735 |
2011 |
Papillary thyroid carcinoma
|
0.400 |
FusionGene
|
disease |
ORPHANET |
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
|
19883730 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activating mutations of the oncogene BRAF or rearrangements of the tyrosine kinase receptor RET are observed in up to 80% of papillary thyroid carcinomas (PTCs).
|
20652698 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These structural changes lead to the formation of fusion genes RET-PTC, TRK(-T), and BRAF-AKAP9, which originate as a result of intrachromosomal or interchromosomal rearrangements and are found in papillary thyroid carcinoma.
|
20951315 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Rearrangements of NTRK1 gene in papillary thyroid carcinoma.
|
19883730 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Eight PTCs expressed two different mutations (1 RET/PTC + BRAF, 6 NTRK1 + BRAF, 1 RET/PTC + NTRK1).
|
20640859 |
2010 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The former group did not differ from the wild-type group in terms of MTC size, prevalence of C-cell hyperplasia (CCH) or papillary thyroid carcinoma (PTC).
|
18331611 |
2008 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Moreover, several gene products with unknown functions were demonstrated in PTCs bearing RET or NTRK1 hybrids versus rearrangement-negative PTCs, including a homologue of the Ig kappa light chain constant region.
|
16256137 |
2006 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Our study is the first one in which the frequency of NTRK1 rearrangements in PTC was reported for the Polish population.
|
16483615 |
2006 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In papillary thyroid carcinoma (PTC), genetic events involve RET and TRK (rearrangements) and BRAF and RAS (mutations), although RAS mutations are uncommon except in the follicular variant of PTC.
|
17131411 |
2006 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatic rearrangement of the tyrosine kinase receptor RET is restricted to papillary thyroid carcinoma (PTC).
|
15876154 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Papillary thyroid carcinomas are marked by a high frequency of chromosome rearrangements involving the RET and NTRK1 tyrosine kinase receptor genes and producing RET and TRK oncogenes.
|
15805251 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
These results, together with data from our previous studies on RAS, RET rearrangements and NTRK1 rearrangements in the same tumours, were compared to determine their individual significance in the pathogenesis of PTCs in Taiwan.
|
16181240 |
2005 |
Papillary thyroid carcinoma
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Alternative mutations of BRAF, RET and NTRK1 are associated with similar but distinct gene expression patterns in papillary thyroid cancer.
|
15273715 |
2004 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Thyroid papillary cancers (PTCs) are associated with activating mutations of genes coding for RET or TRK tyrosine kinase receptors, as well as of RAS genes.
|
12670889 |
2003 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Somatic rearrangements of RET and TRK are almost exclusively found in PTC and may be found in early stages.
|
11165748 |
2001 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
Our results concerning the radiation-associated tumours showed that only rearrangements between NTRK1 and TPM3 genes (TRK oncogene) were detected in 2/14 papillary carcinomas and in one lymph-node metastasis of one of these papillary thyroid carcinomas.
|
10646882 |
2000 |
Papillary thyroid carcinoma
|
0.400 |
Biomarker
|
disease |
BEFREE |
A high prevalence of RET gene rearrangements (62.3%) with a significant predominance of ELE1/RET (PTC3) over H4/RET (PTC1) rearrangements was found in PTCs of the first post-Chernobyl decade.NTRK1 rearrangements were rare (3.3%).
|
10741739 |
2000 |
Papillary thyroid carcinoma
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
The high incidence of yet uncharacterized NTRK1 hybrid mRNAs in our patient cohort leads to the speculation that activating chromosomal rearrangements of several tyrosine kinase receptors may be a common feature of PTCs and that the expression of distinct chimeras may potentially be of prognostic significance.
|
11114633 |
2000 |